Study to Assess the Safety of Treatment of Articular Cartilage Lesions With CartiLife®

Inclusion Criteria: * Patients at least 19 years old * Defect size: 2 to 10 ㎠ on the unilateral knee cartilage (up to 4 ㎤ in volume) * Defect: isolated ICRS (International Cartilage Repair Society) grade III or IV single defect chondral lesion on articular cartilage * The joint space is maintained over 50% relative to baseline * Patients that are able to walk without aid * Patients that agree to abide by strict rehabilitation protocols and follow-up programs * Patients who provide written consent to the participation of the clinical trial Exclusion Criteria: * Patients with inflammatory articular diseases such as rheumatoid arthritis or gouty arthritis * Patients with arthritis associated with autoimmune disease * Patients hypersensitive to bovine protein * Patients with Haemophilia or markedly reduced immune function * Patients hypersensitive to antibiotics such as gentamicin * Patients with arterial bleeding and severe venous bleeding * Patients with other diseases including tumors except for cartilaginous defects of joints * Patients with a history of radiation treatment and chemotherapy within the past two years * Patients who are pregnant, nursing a baby or likely to get pregnant * Patients who participate in concurrent clinical trials or previous clinical trials within 30 days of administration * Other cases where the investigator deems the patient ineligible for participation